Benign prostate hyperplasia (BPH) is a common disorder of men over the age of fifty.  A number of laser based procedures have been developed to treat the disorder.  The potassium titanyl phosphate (KTP) laser has to been used for vaporization of the prostate.  The RevoLix 2 micron continuous wave Laser has been specifically designed to vaporize and incise the prostate with good hemostasis.

This paper reviews the results of 217 patients that were treated over a 12 month period with the new RevoLix Laser.  The age ranged from 52 to 84 with a mean 67.2 years.  The size of the prostate ranged from 32.0 to 187.6 with a mean 68.2 grams.  Prior to laser treatment patients were examined, 47 patients had acute urine retention, 67 patients had diabetes mellititus and 89 patients were on anticoagulants.  Follow-up was from 12 to 116 months.  The RevoLix Laser was used at a power level from 60 to 90 watts.  An endfiring 550 micron fiber was used with a continuous flow 26F cystoscope. VapoResection is a protocol whereby the laser is used to resect and vaporize pieces of prostate similar the traditional transurethral resection of prostate.  Some pieces were flushed out of the bladder with the morcelation. 

All patients experienced 1 to 9 days of mild dysuria and mild hematuria. 11 of 217 (5.1%) patients required catheterization in the first after treatment.  The one year after transurethral VapoResection of Prostate (TUVRP) the mean international prostatic symptom score (IPSS) decreased from 23.2. to 11.8, the mean peak uroflow rate (UFR) increased from 7.5 to 16.2 mL/sec. Only one of 217 (0.4%) patients needed to check bleeding after operation. 13 of 217 (6.0%) patients had urethral stricture or bladder neck contracture 3 - 32 months later after TUVRP. 

However, the results encourage to transurethral vaporesection of prostate using the RevoLix Laser for the treatment of BPH.